BOSTON / May 17, 2023 / Business Wire / Amwell® (NYSE: AMWL), a leader in digital healthcare enablement, today announced the appointment of Kathy Weiler as Executive Vice President, Chief Commercial and Growth Officer, effective June 1, 2023. As a member of Amwell’s executive leadership team, Weiler will lead the company’s growth strategy, driving strategic initiatives and leading the business development, sales and account management, commercial enablement, marketing, and strategic and channel partnerships teams. Weiler will partner with Amwell clients to help them achieve greater clinical, operational and financial outcomes by leveraging the Amwell Converge™ platform to deliver digitally enabled hybrid care solutions at scale.
“The healthcare industry is undergoing a transformation to establish digital-first approaches to hybrid care, connecting all venues of care beyond the traditional four walls of a hospital. Amwell is the digital enablement partner for our clients navigating these complex challenges,” said Amwell CEO Dr. Ido Schoenberg. “We are thrilled to couple Kathy’s world-class experience and leadership with Amwell’s deep knowledge of digital care best practices as we work to enable our clients to achieve important operational and clinical goals.”
Weiler comes to Amwell from Optum where she led consumerism as Chief Consumer Officer. Previously, she was Chief Consumer Strategy Officer at UnitedHealth Group and the Chief Marketing and Experience Officer of Optum Health, leading all marketing efforts for Optum Care and Optum’s Population Health Solutions, Complex Care Management, Medical Benefits Management, Behavioral Health, Prevention and Financial Services businesses. Prior to joining Optum and UnitedHealth Group, Weiler was Chief Marketing, Product and Digital Officer at Blue Cross and Blue Shield of Massachusetts where she drove strategic growth and retention business objectives across all business units. Earlier in her career, she worked with several financial services organizations, including serving as Chief Marketing and Digital Officer of Fidelity Investments FAS business.
“I am honored to join Amwell and work closely with our clients, partners and employees to address the most pressing priorities facing healthcare today, delivering on the promise of digitally enabled hybrid care,” said Weiler.
About Amwell
Amwell is a leading digital care delivery enablement platform in the United States and globally, connecting and enabling providers, insurers, patients, and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that digital care delivery will transform healthcare. The Company offers a single, comprehensive platform to support all digital health needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. With over a decade of experience, Amwell powers the digital care of more than 55 health plans, which collectively represent more than 90 million covered lives, and many of the nation’s largest health systems, representing over 2,000 hospitals, have access to Amwell solutions. For more information, please visit https://business.amwell.com/.
©2023 American Well Corporation. All rights reserved. Amwell®, SilverCloud®, Conversa®, ConvergeTM, CarepointTM and the Amwell Logo are registered trademarks or trademarks of American Well Corporation.
Last Trade: | US$6.98 |
Daily Change: | -0.04 -0.57 |
Daily Volume: | 53,414 |
Market Cap: | US$95.420M |
February 12, 2025 January 15, 2025 December 18, 2024 October 30, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load